The DCR was 80.8%, and the median OS was 12.68 months. 26 patients with metastatic NSCLC who failed to EGFR-TKI treatment were enrolled, the median follow-up was 11.56 months.64 patients with metastatic NSCLC who had failed first-line treatment were enrolled, the median follow-up was 21.6 months and the median OS was 18.40 month s, among 41 patients with non-squamous NSCLC, the median OS was 19.81 months, while among 20 patients with squamous NSCLC, the median OS was 12.88 months.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |